Over the course of the year, Bayer achieved an operational turnaround and laid a good foundation for further growth in all three divisions.
Dusseldorf After the shock of glyphosate legal charges in the billions in 2020, confidence has returned to Bayer shareholders. With an increase of almost 40 percent since the beginning of January, the share is one of the strongest stocks on Europe’s stock exchanges this year.
At first glance, the balance sheet for the past year provides little reason for optimism. Bayer has made little or no progress on key metrics like adjusted earnings, debt, and free cash flow.
However, a precise analysis shows that Bayer managed to turn the operative trend in the course of the year and laid a good foundation for further growth in all three divisions, especially in the pharmaceuticals sector.
CEO Werner Baumann will also be aiming for this in his presentation at the Annual General Meeting next Friday. It is clear to the Bayer Board of Management that it must not disappoint the associated expectations.
Top jobs of the day
Find the best jobs now and
be notified by email.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue